What's Going On With Amgen Stock Tuesday?
In brief
Amgen’s stock slid sharply as the Novartis Phase 3 failure cast doubt on the Lp(a)‑lowering strategy that underpins Amgen’s olpasiran program.
ClearTape summarizes context in-app. For the full publisher article, use Read original source above.